Analytical Data
-
基因名
GRIP1
- Application
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y3R0
-
表达区间
Gly874~Glu1073
-
分子量
26kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GRIP1 (glutamate receptor interacting protein 1) is a critical scaffolding protein involved in the regulation of glutamate receptors and various signaling pathways in the nervous system. Its role in synaptic plasticity and neurotransmission makes it a subject of significant interest in neuroscience research, particularly in understanding the molecular mechanisms underlying learning and memory. Dysregulation of GRIP1 has been implicated in several neurological disorders, including Alzheimer's disease and schizophrenia. Therefore, studying GRIP1 through recombinant protein techniques allows researchers to elucidate its structure-function relationships, interaction dynamics with glutamate receptors, and downstream signaling effects. By employing methods such as recombinant DNA technology and protein purification, scientists can produce GRIP1 in a controlled environment, facilitating detailed investigations into its functional properties and regulatory mechanisms. This research not only enhances our understanding of synaptic biology but also offers potential therapeutic insights for targeting GRIP1-related pathways in various neuropsychiatric conditions.
